MX2023007029A - Masitinib para el tratamiento de la enfermedad de alzheimer. - Google Patents
Masitinib para el tratamiento de la enfermedad de alzheimer.Info
- Publication number
- MX2023007029A MX2023007029A MX2023007029A MX2023007029A MX2023007029A MX 2023007029 A MX2023007029 A MX 2023007029A MX 2023007029 A MX2023007029 A MX 2023007029A MX 2023007029 A MX2023007029 A MX 2023007029A MX 2023007029 A MX2023007029 A MX 2023007029A
- Authority
- MX
- Mexico
- Prior art keywords
- alzheimer
- disease
- masitinib
- treatment
- solvate
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 5
- 239000002139 L01XE22 - Masitinib Substances 0.000 title abstract 4
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004655 masitinib Drugs 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000012453 solvate Substances 0.000 abstract 3
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
La presente invención se refiere a un derivado de 2-aminoariltiazol, en particular masitinib, o una sal o solvato farmacéuticamente aceptable del mismo, para utilizarse en el tratamiento de la enfermedad de Alzheimer menos grave y/o en etapa temprana en un paciente que lo necesita. En particular, la presente invención se refiere a masitinib, o una sal o solvato farmacéuticamente aceptable del mismo, para su uso en el tratamiento de la enfermedad de Alzheimer en un paciente que tiene una puntuación de ADCS-ADL de línea basal (Estudio Cooperativo de la Enfermedad de Alzheimer-Actividades de la Vida Diaria) igual o mayor, preferentemente mayor a 32, con una puntuación de MMSE de línea basal (Mini-Examen del Estado Mental) igual o mayor a 13, con un tiempo desde el diagnóstico hasta el inicio del tratamiento con masitinib, o una sal o solvato farmacéuticamente aceptable del mismo, igual o menor a 5 años, y/o con una puntuación de ADAS-Cog de línea basal (Escala de Evaluación de la Enfermedad de Alzheimer-Subescala Cognitiva) igual o menor a 40.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20306589 | 2020-12-16 | ||
| PCT/EP2021/086308 WO2022129410A1 (en) | 2020-12-16 | 2021-12-16 | Masitinib for the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007029A true MX2023007029A (es) | 2023-07-18 |
Family
ID=74141317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007029A MX2023007029A (es) | 2020-12-16 | 2021-12-16 | Masitinib para el tratamiento de la enfermedad de alzheimer. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240058328A1 (es) |
| EP (1) | EP4262801A1 (es) |
| JP (1) | JP2023554354A (es) |
| KR (1) | KR20230125804A (es) |
| CN (1) | CN116963736A (es) |
| AU (1) | AU2021399925A1 (es) |
| CA (1) | CA3201259A1 (es) |
| IL (1) | IL303521A (es) |
| MX (1) | MX2023007029A (es) |
| WO (1) | WO2022129410A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0313165B8 (pt) | 2002-08-02 | 2021-05-25 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazóis e sua utilização como inibidores de c-kit |
| AU2008214679A1 (en) | 2007-02-13 | 2008-08-21 | Ab Science | Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors |
-
2021
- 2021-12-16 EP EP21839188.6A patent/EP4262801A1/en active Pending
- 2021-12-16 CA CA3201259A patent/CA3201259A1/en active Pending
- 2021-12-16 AU AU2021399925A patent/AU2021399925A1/en active Pending
- 2021-12-16 US US18/256,721 patent/US20240058328A1/en active Pending
- 2021-12-16 JP JP2023536086A patent/JP2023554354A/ja active Pending
- 2021-12-16 CN CN202180093808.7A patent/CN116963736A/zh active Pending
- 2021-12-16 MX MX2023007029A patent/MX2023007029A/es unknown
- 2021-12-16 WO PCT/EP2021/086308 patent/WO2022129410A1/en active Application Filing
- 2021-12-16 KR KR1020237023563A patent/KR20230125804A/ko unknown
- 2021-12-16 IL IL303521A patent/IL303521A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116963736A (zh) | 2023-10-27 |
| WO2022129410A1 (en) | 2022-06-23 |
| JP2023554354A (ja) | 2023-12-27 |
| US20240058328A1 (en) | 2024-02-22 |
| IL303521A (en) | 2023-08-01 |
| AU2021399925A1 (en) | 2023-06-29 |
| EP4262801A1 (en) | 2023-10-25 |
| KR20230125804A (ko) | 2023-08-29 |
| CA3201259A1 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018112446A3 (en) | Use of apoe4 motif-mediated genes for diagnosis and treatment of alzheimer's disease | |
| CN108026146A (zh) | 稳定的抗微生物肽 | |
| WO2006071778A3 (en) | Treatment of parkinson's disease and related disorders using postpartum derived cells | |
| NO20071267L (no) | Forhindring og behandling av synukleinopatiske og amyloidogene sykdommer | |
| WO2004010932A3 (en) | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions | |
| MX2007001679A (es) | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. | |
| UA92181C2 (ru) | Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера | |
| WO2008157747A8 (en) | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders | |
| MX2018001918A (es) | Aplicación cuantitativa periorbital de farmacos oftalmologicos. | |
| EP4245295A3 (en) | Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors | |
| WO2007081486A3 (en) | Oral administration of defensins to treat intestinal diseases | |
| MX2023007029A (es) | Masitinib para el tratamiento de la enfermedad de alzheimer. | |
| MX2023004537A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| CN104434948B (zh) | 一种抗胰腺癌的药物组合物及其应用 | |
| MX2022009285A (es) | Inhibidores macrocíclicos de la quinasa rip2. | |
| ZA202200331B (en) | Naltrexone formulation | |
| CN107184744A (zh) | 番茄红素和葡萄籽提取物的组合物在制药中的用途 | |
| HUP0201478A2 (hu) | Neuroprotektív és retinoprotektív szemészeti gyógyszerek | |
| MX2023002350A (es) | Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| US20210162047A1 (en) | A Drug For Treating Disorders Of An Organ Or Tissue Function And Diseases Accompanied By Such Disorders, And The Method For Obtaining It. | |
| MX2021014093A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| AU2020299145A8 (en) | Compositions and methods for treating eye diseases | |
| Patejdl et al. | Severe acute motor neuropathy after treatment with triple tyrosine kinase inhibitor BIBF 1120 (Nintedanib) | |
| EP1902725A3 (en) | Revascularization of ischemic retinal tissue |